Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
DMRA Operating Income
Profit from core operations after operating expenses, before interest and taxes.
Damora Therapeutics, Inc.NASDAQ: DMRA
Operating Income · Q1 FY2026 · quarter ended Mar 2026
Operating income remains negative
Q1 FY2026 operating income was -$30.81M, compared with -$2.6M a year earlier. Trailing-twelve-month operating income was -$239.08M.
Context
- Operating income grew in size in 1 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether operating income reaches the consensus estimate of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -1148.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$30.81M+84.7% QoQ
- Last fiscal yearDec 2025
- -$210.87M-1148.0% YoY
- LTMMar 2026
- -$239.08M-1638.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1085.5% | +100.0% | +1185.5 pp |
| 1 year | -1148.0% | +100.0% | +1248.0 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Operating Income history
USD · from the income statement
- Latest · FY2025
- (210.87M) USD
- Year-over-year change
- -1148.0%
| Period | Period end | Operating Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (210.87M) | -1148.0% |
| FY2024 | 2024-12-31 | (16.9M) | +53.7% |
| FY2023 | 2023-12-31 | (36.46M) | +40.4% |
| FY2022 | 2022-12-31 | (61.21M) | -17.2% |
| FY2021 | 2021-12-31 | (52.23M) | — |
Operating Income vs competitors
How DMRA compares with its peers on the latest reported figures
- DMRA's LTM Mar 2026 operating income of -$239.08M is the 8th highest of the 9 companies compared; the peer median is -$53.74M.
- Its year-over-year change of -1638.2% is the lowest of 7, against a peer median of +29.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $1.84B | +89.2% | +31.4% | 31.6% | |
| LTM Jun 2026 | $1.33B | — | -41.6% | 32.3% | |
| LTM Mar 2026 | $124.58M | +183.6% | — | 41.6% | |
| LTM Mar 2026 | -$37.37M | +72.2% | — | 19.1% | |
COAGHemab Therapeutics Holdings, Inc. Common Stock | FY2025 | -$70.12M | — | — | — |
| LTM Mar 2026 | -$110.35M | -970.3% | — | 332.6% | |
| LTM Mar 2026 | -$191.33M | -12.9% | — | 1057.5% | |
DMRADamora Therapeutics, Inc. | LTM Mar 2026 | -$239.08M | -1638.2% | — | — |
IRONDisc Medicine, Inc. | LTM Sep 2026 | -$265.73M | -30.5% | — | — |
| Peer median (excluding DMRA) | -$53.74M | +29.6% | -5.1% | 36.9% | |
Competitors are the stored peer set for DMRA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 441K | 490K | 830K | 181K | 0 |
| Gross Profit | (441K) | (490K) | (830K) | (181K) | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 38.49M | 48.21M | 23.77M | 6.4M | 201.19M |
| Selling, General & Admin | 13.3M | 12.51M | 11.86M | 10.32M | 9.69M |
| Operating Expenses | 51.79M | 60.72M | 35.63M | 16.72M | 210.87M |
| Depreciation & Amortization | 441K | 490K | 830K | 181K | 34K |
| EBITDA | (51.31M) | (61.13M) | (37.52M) | (21.22M) | (209.76M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (52.23M) | (61.21M) | (36.46M) | (16.9M) | (210.87M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 156K | 722K | 1.69M | 844K | 1.17M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 475K | (417K) | (1.89M) | (4.5M) | 1.08M |
| Income Before Tax | (51.75M) | (61.62M) | (38.35M) | (21.4M) | (209.79M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 41K | 50K |
| Net Income | (51.75M) | (61.62M) | (38.35M) | (21.44M) | (209.84M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| EPS (Diluted) | (51.22) | (60.63) | (36.08) | (18.53) | (158.13) |
| Weighted Avg Shares | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
| Weighted Avg Shares (Diluted) | 1.01M | 1.02M | 1.06M | 1.16M | 1.33M |
Damora Therapeutics, Inc.
NASDAQ:DMRA
Intrinsic Alpha fair value
Locked
Current Price
$22.98
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.